Page 53 - GPD-3-4

Gene & Protein in Disease Immune checkpoint blocker and NK cell activation

anti-tumor strategy. In a murine tumor model, treatment References
111
with SN38, a pharmacological immuno-activator and 1. Smith SM, Wachter K, Burris HA 3 , et al. Clinical cancer
rd
DNA replication inhibitor, significantly reduced PD-L1 advances 2021: ASCO’s report on progress against cancer.
expression and enhanced FOXO3 expression. This J Clin Oncol. 2021;39(10):1165-1184.
112
therapy also engaged tumor-infiltrating NKG2D-positive
NK cells in an IFN-γ and granzyme-B-dependent doi: 10.1200/jco.20.03420
manner. In addition, combination therapy with anti- 2. Sadeghi Rad H, Monkman J, Warkiani ME, et al.
112
PD-L1 and anti-sMIC improved overall survival rates in Understanding the tumor microenvironment for effective
B16DF10 melanoma mice compared to monotherapy with immunotherapy. Med Res Rev. 2021;41(3):1474-1498.
either anti-sMIC or PD-L1/PD-1 blockage. 101 doi: 10.1002/med.21765
4. Conclusion 3. Thorsson V, Gibbs DL, Brown SD, et al. The immune
landscape of cancer. Immunity. 2018;48(4):812-830.e14.
The data discussed above indicate that the development
of a chimeric protein that simultaneously targets NKG2D doi: 10.1016/j.immuni.2018.03.023
and ICBs represents a novel approach to enhancing 4. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint
NK-cell- and T cell-mediated cytotoxicity in TME. blockade: A common denominator approach to cancer
We propose that by fusing the extracellular domain of therapy. Cancer Cell. 2015;27(4):450-461.
MICA, which engages NKG2D on NK cells, with the doi: 10.1016/j.ccell.2015.03.001
variable regions of an anti-PD-L1 antibody, a bifunctional 5. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-
therapeutic agent could be created. This agent will CTLA-4 therapies in cancer: Mechanisms of action, efficacy,
(i) inhibit the PD-L1/PD-1 interaction between T cells and and limitations. Front Oncol. 2018;8:86.
tumor cells, thereby reactivating T-cell cytotoxicity and
(ii) engage with NKG2D to enhance NK cell cytotoxicity doi: 10.3389/fonc.2018.00086
(Figure 1). Once the bifunctional fusion protein’s activity 6. André P, Denis C, Soulas C, et al. Anti-NKG2A mAb
is confirmed in vitro and in animal models, it could be is a checkpoint inhibitor that promotes anti-tumor
rapidly advanced to clinical trials. This development would immunity by unleashing both T and NK cells. Cell.
provide cancer patients, particularly those with PD-L1- 2018;175(7):1731-1743.e13.
positive cancers, with a promising new treatment option. doi: 10.1016/j.cell.2018.10.014

Acknowledgment 7. Carotta S. Targeting NK cells for anticancer immunotherapy:
Clinical and preclinical approaches. Front Immunol.
None. 2016;7:152.

Funding doi: 10.3389/fimmu.2016.00152
None. 8. Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC,
Moretta L. Human NK cells: Surface receptors, inhibitory
Conflict of interest checkpoints, and translational applications. Cell Mol
Immunol. 2019;16(5):430-441.
The authors declare no conflict of interest to any group.
doi: 10.1038/s41423-019-0206-4
Author contributions 9. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH.
Coinhibitory pathways in immunotherapy for cancer. Annu
Conceptualization: All authors Rev Immunol. 2016;34:539-573.
Writing – original draft: All authors
Writing – review & editing: All authors doi: 10.1146/annurev-immunol-032414-112049
10. Rolfo C, Caglevic C, Santarpia M, et al. Immunotherapy in
Ethics approval and consent to participle NSCLC: A promising and revolutionary weapon. Adv Exp

Not applicable. Med Biol. 2017;995:97-125.
doi: 10.1007/978-3-319-53156-4_5
Consent for publication
11. Li JX, Huang JM, Jiang ZB, et al. Current clinical progress
Not applicable. of PD-1/PD-L1 immunotherapy and potential combination
treatment in non-small cell lung cancer. Integr Cancer Ther.
Availability of data 2019;18:1534735419890020.
Not applicable. doi: 10.1177/1534735419890020

Volume 3 Issue 4 (2024) 5 doi: 10.36922/gpd.3804